This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Francesc Artigas, PhD
Department of Neurochemistry Consejo Superior de Investigaciones Cientificas Jordi Girona 18-26 Barcelona E-08034, Spain

Arch Gen Psychiatry. 1995;52(11):969-971.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

I read with interest the letter by Howland¹ in the February issue of the ARCHIVES on the use of pindolol to augment antidepressant effects.² Howland argues that pindolol could be acting through β-adrenergic receptors to potentiate the effects of 5-hydroxytryptamine (5-HT) reuptake inhibitors and monoamine oxidase inhibitors. Based on the augmentation of antidepressant effects induced by buspirone hydrochloride,³ a partial 5-HT_1A agonist, he also found it difficult to reconcile the fact that agonists and antagonists of the same receptors may produce the same effect. It is important to clarify this issue because it may be critical to understanding the mode of action of pindolol and other Potentially useful 5-HT_1A antagonists.

The 5-HT_1A receptors are anatomically and pharmacologically heterogeneous. They are localized on the soma and dendrites of serotonergic neurons in the raphe nuclei (presynaptic or somatodendritic location) or on other cell types, in limbic . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?